Stay updated on ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The clinical trial page now presents the record for the ARV-471 and everolimus study in advanced or metastatic ER+/HER2- breast cancer, including its design, eligibility criteria, outcome measures, and locations, rather than an error page.
    Difference
    47%
    Check dated 2026-11-08T13:56:09.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.2 to v3.8.0; the study record still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T15:09:09.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    A sitewide banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” and links to transition updates and FAQs.
    Difference
    1%
    Check dated 2026-10-25T14:01:01.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The error page’s footer revision identifier changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-18T14:31:01.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision label changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-11T15:13:11.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    Added a 403 Forbidden error page state with basic HTML boilerplate, indicating access is blocked; the surrounding site chrome remains visible, meaning this is an access issue rather than a content update.
    Difference
    17%
    Check dated 2026-09-20T20:16:27.000Z thumbnail image

Stay in the know with updates to ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial page.